Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.

Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.

Competitive strengths

  • Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
  • Export products in Europe, Latin America, North America, Japan, and the rest of the world.
  • Strong relationship with leading global generic companies.
  • Proven track record of strong financial performance.
  • High-quality product manufacturing with R&D infrastructure.

Company Promoters:

Glenmark Pharmaceuticals Limited is the promoter of the company.

Company Financials:

Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (₹ in million)
31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 19,970.75 17,256.04 14,753.95
Total Revenue 18,859.76 15,493.03 8,868.65
Profit After Tax 3,515.81 3,130.98 1,955.92

Objects of the Issue:

  • To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
  • To finance capital expenditure requirements.
  • To meet general corporate purposes.

Glenmark Life Sciences IPO Details

IPO Opening Date Jul 27, 2021
IPO Closing Date Jul 29, 2021
Issue Type Book Built Issue IPO
Face Value ₹2 per equity share
IPO Price ₹695 to ₹720 per equity share
Market Lot 20 Shares
Min Order Quantity 20 Shares
Listing At BSE, NSE
Issue Size[.] Eq Shares of ₹2
(aggregating up to ₹1,513.60 Cr)
Fresh Issue[.] Eq Shares of ₹2
(aggregating up to ₹1,060.00 Cr)
Offer for Sale6,300,000 Eq Shares of ₹2
(aggregating up to ₹453.60 Cr)

Glenmark Life Sciences IPO Tentative Timetable

The Glenmark Life Sciences IPO open date is Jul 27, 2021, and the close date is Jul 29, 2021. The issue may list on Aug 6, 2021.

IPO Open Date Jul 27, 2021
IPO Close Date Jul 29, 2021
Basis of Allotment Date Aug 3, 2021
Initiation of Refunds Aug 4, 2021
Credit of Shares to Demat Account Aug 5, 2021
IPO Listing Date Aug 6, 2021

Glenmark Life Sciences IPO Lot Size

The Glenmark Life Sciences IPO market lot size is 20 shares. A retail-individual investor can apply for up to 13 lots (260 shares or ₹187,200).

Application Lots Shares Amount (Cut-off)
Minimum 1 20 ₹14,400
Maximum 13 260 ₹187,200

Glenmark Life Sciences IPO Promoter Holding

Pre Issue Share Holding 100%
Post Issue Share Holding 82.84%

Glenmark Life Sciences IPO Subscription Status (Bidding Detail)

The Glenmark Life Sciences IPO is subscribed 44.17x times on Jul 29, 2021 17:01. The public issue subscribed 14.63x in the retail category, 36.97x in the QIB category, and 122.54x in the NII category. Check Day by Day Subscription Details (Live Status)

CategoryIPO Subscription








* Application wise IPO Subscription in Retail: 11


Listing Date Friday, August 6, 2021
BSE Script Code 543322
NSE Symbol GLS
Listing In B Group of Securities
ISIN INE03Q201024
IPO Price ₹720 per equity share
Face Value ₹2 per equity share
IPO Price
Last Trade

Glenmark Life Sciences Limited
Plot No. 170-172, Chandramouli Industrial Estate,
Mohol Bazarpeth, Solapur 413 213,

Phone: +91 2189 234456/ +91 2189

Glenmark Life Sciences IPO FAQs

Glenmark Life Sciences IPO is a main-board IPO of [.] equity shares of the face value of ₹2 aggregating up to ₹1,513.60 Crores. The issue is priced at ₹695 to ₹720 per equity share. The minimum order quantity is 20 Shares.

The IPO opens on Jul 27, 2021, and closes on Jul 29, 2021.

KFintech Private Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Zerodha customers can apply online in Glenmark Life Sciences IPO using UPI as a payment gateway. Zerodha customers can apply in Glenmark Life Sciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.

Steps to apply in Glenmark Life Sciences IPO through Zerodha

  1. Visit the Zerodha website and login to Console.
  2. Go to Portfolio and click the IPOs link.
  3. Go to the Glenmark Life Sciences IPO row and click the Bid button.
  4. Enter your UPI ID, Quantity, and Price.
  5. ‘Submit’ IPO application form.
  6. Visit the UPI App (net banking or BHIM) to approve the mandate.

Visit Zerodha IPO Application Process Review for more detail.

The Glenmark Life Sciences IPO opens on Jul 27, 2021 and closes on Jul 29, 2021.

Glenmark Life Sciences IPO lot size is 20 Shares and the minimum order quantity is 20 Shares.

You can apply in Glenmark Life Sciences IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who dont offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Edelweiss, ICICI Bank, HDFC Bank and SBI Bank.

The finalization of Basis of Allotment for Glenmark Life Sciences IPO will be done on Aug 3, 2021, and the allotted shares will be credited to your demat account by Aug 5, 2021. Check the Glenmark Life Sciences IPO allotment status.

The Glenmark Life Sciences IPO listing date is on Friday, August 6, 2021.


Say hello

Find us at the office

Chappa- Adamitis street no. 38, 81811 Tripoli, Libya

Give us a ring

Alda Runion
+69 213 130 910
Mon - Fri, 10:00-22:00

Say hello